A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells

Leukemia

Volumn 23, Issue 1, 2009, Pages 71-77

  Otz, T ^a   Grosse Hovest L ^a   Hofmann, M ^a   Rammensee, H G ^a   Jung, G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; CD28 ANTIBODY; CD28 ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL DESTRUCTION;

EID: 58249122185     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.271     Document Type: Article

References (19)

1. Zang X, Allison JP. The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 2007; 13 (18 Part 1): 5271-5279.
2. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239-247.
3. Elflein K, Rodriguez-Palmero M, Kerkau T, Hunig T. Rapid recovery from T lymphopenia by CD28 superagonist therapy. Blood 2003; 102: 1764-1770.
4. Beyersdorf N, Hanke T, Kerkau T, Hunig T. Superagonistic anti-CD28 antibodies: Potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis 2005; 64 (Suppl 4): iv91-iv95.
5. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
6. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003; 33: 1334-1340.
7. Grosse-Hovest L, Muller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 2004; 101: 6858-6863.
8. Grosse-Hovest L, Wick W, Minoia R, Weller M, Rammensee HG, Brem G et al. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 2005; 117: 1060-1064.
9. Liu AY, Robinson RR, Murray Jr ED, Ledbetter JA, Hellstrom I, Hellstrom KE. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987; 139 3521-3526.
10. Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 1991; 21: 2431-2435.
11. Ceme rlic D, Dadey B, Han T, Vaickus L. Cytokine influence on killing of fresh chronic lymphocytic leukemia cells by human leukocytes. Blood 1991; 77: 2707-2715.
12. Rossi E, Matutes E, Morilla R, Owusu-Ankomah K, Heffernan AM, Catovsky D. Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996; 10: 494-497.
13. Frydecka I, Kosmaczewska A, Bocko D, Ciszak L, Wolowiec D, Kuliczkowski K et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 2004; 90: 2042-2048.
14. Tacke M, Hanke G, Hanke T, Hunig T. CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28. Eur J Immunol 1997; 27: 239-247.
15. Kunicka JE, Platsoucas CD. Defective helper function of purified T4 cells and excessive suppressor activity of purified T8 cells in patients with B-cell chronic lymphocytic leukemia. T4 suppressor effector cells are present in certain patients. Blood 1988; 71: 1551-1560.
16. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: New insights into biology and therapy. Ann Intern Med 1990; 113: 525-539.
17. Platsoucas CD, Galinski M, Kempin S, Reich L, Clarkson B, Good RA. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: An analysis by monoclonal antibodies. J Immunol 1982; 129: 2305-2312.
18. Totterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989; 74: 786-792.
19. Brandl M, Grosse-Hovest L, Holler E, Kolb HJ, Jung G. Bispecific antibody fragments with CD20 × CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma. Exp Hematol 1999; 27: 1264-1270.